Mitochondrial impairment and downregulation of Drp1 phosphorylation underlie the antiproliferative and proapoptotic effects of alantolactone on oral squamous cell carcinoma cells

• Published in: Journal of translational medicine 2023-05, Vol.21 (1), p.328-328, Article 328
• Main Authors: Zhang, Yafei, Yang, Bingqian, Tu, Chengwei, Ping, Yifan, Chen, Shuhong, Wu, Tong, Zhao, Zheyu, Mao, Yixin, Yang, Zhan, Cao, Zelin, Li, Jianmin, Huang, Kate, Ding, Xi, Wu, Gang, Zou, Peng, Deng, Zhennan, Sun, Xiaoyu
• Format: Article
• Language: English
• Subjects: Acetylcysteine; Adenosine triphosphate; Adenosine Triphosphate - metabolism; Alantolactone (ALT); Analysis; Annexin V; Antibodies; Apoptosis; Bioinformatics; Cancer therapies; Care and treatment; Cell culture; Cell injury; Cell Line, Tumor; Cell proliferation; Cell viability; Depolarization; Diagnosis; Down-Regulation; Dynamin; Dynamin-related protein 1 (Drp1); Dynamins - metabolism; Dynamins - pharmacology; Dynamins - therapeutic use; Flow cytometry; Genes; Homeostasis; Humans; Immunohistochemistry; Medical prognosis; Medical research; Membrane potential; Metabolism; Mitochondria; Mitochondria - metabolism; Mitochondrial DNA; Mitochondrial impairment; Mouth cancer; Mouth Neoplasms - drug therapy; Mouth Neoplasms - pathology; Oral cancer; Oral carcinoma; Oral squamous cell carcinoma; Oral squamous cell carcinoma (OSCC); Phosphorylation; Plasmids; Proteins; Reactive nitrogen species; Reactive oxygen species; Reactive oxygen species (ROS); Reactive Oxygen Species - metabolism; Software; Squamous cell carcinoma; Squamous Cell Carcinoma of Head and Neck - drug therapy; Squamous Cell Carcinoma of Head and Neck - pathology; Therapeutic targets
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/s12967-023-04188-2

Oral squamous cell carcinoma (OSCC) is one of the most prevalent and fatal oral cancers. Mitochondria-targeting therapies represent promising strategies against various cancers, but their applications in treating OSCC are limited. Alantolactone (ALT) possesses anticancer properties and also regulates mitochondrial events. In this study, we explored the effects of ALT on OSCC and the related mechanisms. The OSCC cells were treated with varying concentrations and duration of ALT and N-Acetyl-L-cysteine (NAC). The cell viability and colony formation were assessed. The apoptotic rate was evaluated by flow cytometry with Annexin V-FITC/PI double staining. We used DCFH-DA and flow cytometry to detect reactive oxygen species (ROS) production and DAF-FM DA to investigate reactive nitrogen species (RNS) level. Mitochondrial function was reflected by mitochondrial reactive oxygen species (ROS), mitochondrial membrane potential (MMP), and ATP levels. KEGG enrichment analyses determined the mitochondrial-related hub genes involved in OSCC progression. Dynamin-related protein 1 (Drp1) overexpression plasmids were further transfected into the cells to analyze the role of Drp1 in OSCC progression. Immunohistochemistry staining and western blot verified the expression of the protein. ALT exerted anti-proliferative and pro-apoptosis effects on OSCC cells. Mechanistically, ALT elicited cell injury by promoting ROS production, mitochondrial membrane depolarization, and ATP depletion, which were reversed by NAC. Bioinformatics analysis showed that Drp1 played a crucial role in OSCC progression. OSCC patients with low Drp1 expression had a higher survival rate. The OSCC cancer tissues presented higher phosphorylated-Drp1 and Drp1 levels than the normal tissues. The results further showed that ALT suppressed Drp1 phosphorylation in OSCC cells. Moreover, Drp1 overexpression abolished the reduced Drp1 phosphorylation by ALT and promoted the cell viability of ALT-treated cells. Drp1 overexpression also reversed the mitochondrial dysfunction induced by ALT, with decreased ROS production, and increased mitochondrial membrane potential and ATP level. ALT inhibited proliferation and promoted apoptosis of oral squamous cell carcinoma cells via impairment of mitochondrial homeostasis and regulation of Drp1. The results provide a solid basis for ALT as a therapeutic candidate for treating OSCC, with Drp1 being a novel therapeutic target in treating OSCC.